Amonafide malate
Alternative Names: Amonafide L-malate; Amonafide maleate; AS 1413; XanafideLatest Information Update: 02 Oct 2021
At a glance
- Originator Xanthus Pharmaceuticals
- Developer Antisoma; Xanthus Pharmaceuticals
- Class Amines; Antineoplastics; Isoquinolines; Naphthalimides; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Acute myeloid leukaemia
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Breast cancer; Prostate cancer
Most Recent Events
- 31 Jan 2011 Discontinued - Phase-III for Acute myeloid leukaemia in Australia (IV)
- 31 Jan 2011 Discontinued - Phase-III for Acute myeloid leukaemia in Canada (IV)
- 31 Jan 2011 Discontinued - Phase-III for Acute myeloid leukaemia in Eastern Europe (IV)